Form 10-Q · Quarterly report
Regeneron Pharmaceuticals 10-Q, filed Oct 30, 2026
- Filed
- CIK
- 0000872589
- Accession no.
- 0000872589-26-000034
Summary
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.12 billion and net income of $1.95 billion, or $18.45 per diluted share, versus $3.75 billion and $1,460.0 million a year earlier. Combined global sales of EYLEA HD and EYLEA fell 11% to $1.74 billion as EYLEA declined 49%, while global Dupixent sales, recorded by Sanofi, rose 35% to $6.54 billion.
Key points
- Third-quarter 2026 revenue was $5,115.8 million, up from $3,754.3 million in the same period of 2025, and nine-month revenue was $13,011.9 million versus $10,458.6 million.
- Nine-month diluted net income per share was $37.37, compared with $33.61 a year earlier.
- EYLEA HD sales rose 63% to $1,082.8 million in the quarter, while EYLEA sales fell 49% to $658.4 million.
- Libtayo sales rose 51% to $550.0 million in the quarter, and Kevzara sales rose 66% to $255.6 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.